Sanofi Price to Book Ratio 2012-2026 | SNY
Historical price to book ratio values for Sanofi (SNY) over the last 10 years. The current price to book ratio for Sanofi as of June 12, 2026 is 1.41.
| Sanofi Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-06-12 | 44.25 | 0.00 | |
| 2026-03-31 | 45.65 | 0.00 | |
| 2025-12-31 | 45.91 | 0.00 | |
| 2025-09-30 | 44.72 | 0.00 | |
| 2025-06-30 | 45.77 | $32.49 | 1.41 |
| 2025-03-31 | 50.32 | 0.00 | |
| 2024-12-31 | 43.76 | $33.35 | 1.31 |
| 2024-09-30 | 52.28 | 0.00 | |
| 2024-06-30 | 44.02 | $31.04 | 1.42 |
| 2024-03-31 | 42.30 | 0.00 | |
| 2023-12-31 | 43.28 | $31.81 | 1.36 |
| 2023-09-30 | 46.69 | 0.00 | |
| 2023-06-30 | 46.91 | $31.50 | 1.49 |
| 2023-03-31 | 45.58 | 0.00 | |
| 2022-12-31 | 40.56 | $31.40 | 1.29 |
| 2022-09-30 | 31.84 | 0.00 | |
| 2022-06-30 | 41.90 | 0.00 | |
| 2022-03-31 | 41.37 | 0.00 | |
| 2021-09-30 | 38.85 | 0.00 | |
| 2021-03-31 | 38.41 | 0.00 | |
| 2020-09-30 | 38.96 | 0.00 | |
| 2020-03-31 | 32.73 | 0.00 | |
| 2019-09-30 | 34.69 | 0.00 | |
| 2019-03-31 | 31.83 | 0.00 | |
| 2018-03-31 | 27.42 | 0.00 | |
| 2017-12-31 | 29.42 | $26.26 | 1.12 |
| 2017-09-30 | 34.06 | 0.00 | |
| 2017-06-30 | 32.78 | $25.22 | 1.30 |
| 2017-03-31 | 29.97 | 0.00 | |
| 2016-12-31 | 26.79 | $24.72 | 1.08 |
| 2016-09-30 | 25.30 | 0.00 | |
| 2016-06-30 | 27.72 | $23.85 | 1.16 |
| 2016-03-31 | 25.53 | 0.00 | |
| 2015-09-30 | 30.18 | 0.00 | |
| 2015-06-30 | 31.48 | $23.95 | 1.31 |
| 2014-06-30 | 32.71 | 0.00 | |
| 2013-06-30 | 30.57 | 0.00 | |
| 2012-06-30 | 21.67 | 0.00 | |
| 2012-03-31 | 21.20 | 0.00 | |
| 2011-12-31 | 19.99 | 0.00 | |
| 2011-09-30 | 17.94 | 0.00 | |
| 2011-06-30 | 21.97 | 0.00 | |
| 2011-03-31 | 18.38 | 0.00 | |
| 2010-12-31 | 16.82 | 0.00 | |
| 2010-09-30 | 17.35 | 0.00 | |
| 2010-06-30 | 15.69 | 0.00 | |
| 2010-03-31 | 18.49 | 0.00 | |
| 2009-12-31 | 19.43 | 0.00 | |
| 2009-09-30 | 18.28 | 0.00 | |
| 2009-06-30 | 14.59 | 0.00 | |
| 2009-03-31 | 13.11 | 0.00 | |
| 2008-12-31 | 15.10 | 0.00 | |
| 2008-09-30 | 15.43 | 0.00 | |
| 2008-06-30 | 15.60 | 0.00 | |
| 2008-03-31 | 16.93 | 0.00 | |
| 2007-12-31 | 20.54 | 0.00 | |
| 2007-09-30 | 19.13 | 0.00 | |
| 2007-06-30 | 18.16 | 0.00 | |
| 2007-03-31 | 19.16 | 0.00 | |
| 2006-12-31 | 20.33 | 0.00 | |
| 2006-09-30 | 19.58 | 0.00 | |
| 2006-06-30 | 21.44 | 0.00 | |
| 2006-03-31 | 20.49 | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |